Tocilizumab: A review in rheumatoid arthritis
Open accessAbstract
), an IL-6 receptor antagonist, are approved (± methotrexate) in numerous countries throughout the world, for the treatment of adults with moderate to severe active rheumatoid arthritis (RA). Extensive clinical experience has firmly established the short- and long-term efficacy and safety of tocilizumab [monotherapy or in combination with conventional synthetic DMARDs (csDMARDs)] in adults with early-stage and longer-duration established RA. In the clinical trial and real-world settings, tocilizumab monotherapy or combination therapy provided rapid and sustained improvements in clinical and radiographic outcomes and health-related quality of life. The safety profile of tocilizumab is consistent over time and, in general, is consistent with that of other immunomodulatory agents. This narrative review, written from an EU perspective, summarizes the clinical use of IV and SC tocilizumab in RA. Given its low risk of immunogenicity, the flexibility of IV and SC administration and the convenience of the once-weekly, self-administered, SC regimen, tocilizumab provides an effective treatment for severe, active and progressive RA in adults not previously treated with methotrexate and an effective biologic first- or subsequent-line treatment for moderate to severe active RA in adults who have either responded inadequately to or were intolerant of previous therapy with ≥ 1 csDMARD or TNF inhibitor.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Subcutaneous and intravenous formulations of tocilizumab exhibit similar short- and long-term efficacy and safety profiles in clinical trial and clinical practice settings.
“Moreover, s.c. and i.v.formulations exhibit similar short-and long-term efficacy and safety profiles in clinical trial and clinical practice settings.113”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [113]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Smolen, J. S., Landewé, R., Bijlsma, J. W. J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 7,468 · see citing works
The Pathogenesis of Rheumatoid Arthritis
McInnes, I. B., & Schett, G. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004965 · Cited by 5,514 · see citing works
Smolen, J. S., Breedveld, F. C., Burmester, G. R., Bykerk, V. P., Dougados, M., Emery, P., Kvien, T. K., Navarro-Compán, M. V., Oliver, S. M., Schoels, M., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207524 · Cited by 1,481 · see citing works
Smolen, J. S., Beaulieu, A. D., Rubbert‐Roth, A., Ramos-Remus, C., Rovensky, J., Alecock, E., WOODWORTH, T. G., & Alten, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60453-5 · Cited by 1,399 · see citing works
Emery, P., Keystone, E., Tony, H. P., Cantagrel, A., van Vollenhoven, R., Sanchez, A., Alecock, E., Lee, J., & Kremer, J. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092932 · Cited by 1,104 · see citing works
Genovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., Woodworth, T., & Gomez‐Reino, J. J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23940 · Cited by 855 · cited 9× · see citing works
“TOWARD (24) [12] DMARD-IR TCZ?DMARD 803 61*** 38*** 21*** 30***”
BackgroundInfluentialJones, G., Sebba, A., Gu, J., Lowenstein, M. B., Calvo, A., Gomez-Reino, J. J., Siri, D. A., Tomšič, M., Alecock, E., Woodworth, T., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.105197 · Cited by 797 · see citing works
Nishimoto, N., Hashimoto, J., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Murata, N., van der Heijde, D. M. F. M., & Kishimoto, T. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.068064 · Cited by 727 · see citing works
Gabay, C., Emery, P., van Vollenhoven, R., Dikranian, A., Alten, R., Pavelka, K., Klearman, M., Musselman, D., Agarwal, S., Green, J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60250-0 · Cited by 672 · see citing works
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
van Schouwenburg, P. A., Rispens, T., & Wolbink, G. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.4 · Cited by 441 · see citing works
Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE
Symmons, D. P. M., & Gabriel, S. E. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.75 · Cited by 406 · see citing works
Kremer, J. M., Blanco, R., Brzosko, M., Burgos‐Vargas, R., Halland, A.-M., Vernon, E., Ambs, P., & Fleischmann, R. (2010) · Arthritis & Rheumatism · doi:10.1002/art.30158 · Cited by 405 · see citing works
Integrated safety in tocilizumab clinical trials
Schiff, M., Kremer, J., Jahreis, A., Vernon, E., Isaacs, J., & van Vollenhoven, R. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3455 · Cited by 348 · see citing works
Dougados, M., Kissel, K., Sheeran, T. P., Tak, P. P., Conaghan, P. G., Mola, E. M., Schett, G. A., Amital, H., Navarro-Sarabia, F., Hou, A., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201282 · Cited by 288 · see citing works
Bijlsma, J. W. J., Welsing, P. M. J., WOODWORTH, T. G., Middelink, L. M., Pethö‐Schramm, A., Bernasconi, C., Borm, M. E. A., Wortel, C. H., ter Borg, E. J., Jahangier, Z. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30363-4 · Cited by 248 · see citing works
Kim, S. C., Solomon, D. H., Rogers, J. R., Gale, S. L., Klearman, M., Sarsour, K., & Schneeweiß, S. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40084 · Cited by 196 · see citing works
The changing landscape of biosimilars in rheumatology
Dörner, T., Strand, V., Cornes, P., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209166 · Cited by 195 · see citing works
Koike, T., Harigai, M., Inokuma, S., Ishiguro, N., Ryu, J., Takeuchi, T., Takei, S., Tanaka, Y., Sano, Y., Yaguramaki, H., et al. (2014) · Journal of Rheumatology · doi:10.3899/jrheum.130466 · Cited by 194 · see citing works
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
Burmester, G. R., Rigby, W. F., van Vollenhoven, R. F., Kay, J., Rubbert-Roth, A., Kelman, A., Dimonaco, S., & Mitchell, N. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207628 · Cited by 194 · see citing works
Strangfeld, A., Richter, A., Siegmund, B., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209773 · Cited by 193 · see citing works
Xie, F., Yun, H., Bernatsky, S., & Curtis, J. R. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39761 · Cited by 175 · see citing works
Nishimoto, N., Ito, K., & Takagi, N. (2010) · Modern Rheumatology · doi:10.3109/s10165-010-0279-5 · Cited by 172 · see citing works
Yazıcı, Y., Curtis, J. R., Ince, A., Baraf, H. S. B., Malamet, R., Teng, L. L., & Kavanaugh, A. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.148700 · Cited by 155 · see citing works
Nishimoto, N., Ito, K., & Takagi, N. (2010) · Modern Rheumatology · doi:10.1007/s10165-010-0279-5 · Cited by 154 · see citing works
Hoeltzenbein, M., Beck, E., Rajwanshi, R., Skorpen, C. G., Berber, E., Schaefer, C., & Østensen, M. (2016) · Seminars in Arthritis & Rheumatism · doi:10.1016/j.semarthrit.2016.05.004 · Cited by 151 · see citing works
Overview of safety of non-biologic and biologic DMARDs
Ruderman, E. (2012) · Lara D. Veeken · doi:10.1093/rheumatology/kes283 · Cited by 149 · see citing works
Dougados, M., Kissel, K., Conaghan, P., Mola, E., Schett, G., Gerli, R., Hansen, M., Amital, H., Xavier, R., Troum, O., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204761 · Cited by 143 · see citing works
Ogata, A., Tanimura, K., Sugimoto, T., Inoue, H., Urata, Y., Matsubara, T., Kondo, M., Ueki, Y., Iwahashi, M., Tohma, S., et al. (2014) · Arthritis Care & Research · doi:10.1002/acr.22110 · Cited by 140 · see citing works
Genovese, M., Rubbert-Roth, A., Smolen, J., Kremer, J., Khraishi, M., Gómez-Reino, J., Sebba, A., Pilson, R., Williams, S., & van Vollenhoven, R. (2013) · Journal of Rheumatology · doi:10.3899/jrheum.120687 · Cited by 139 · see citing works
Kivitz, A., Olech, E., Borofsky, M., Zazueta, B., Navarro-Sarabia, F., Radominski, S., Merrill, J., Rowell, L., Nasmyth‐Miller, C., Bao, M., et al. (2014) · Arthritis care & research · doi:10.1002/acr.22384 · Cited by 137 · see citing works
An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy
Rao, V. U., Pavlov, A., Klearman, M., Musselman, D., Giles, J. T., Bathon, J., Sattar, N., & Lee, J. S. (2015) · Arthritis & Rheumatology · doi:10.1002/art.38920 · Cited by 118 · see citing works
Burmester, G., Rubbert-Roth, A., Cantagrel, A., Hall, S., Leszczyński, P., Feldman, D., Rangaraj, M. J., Roane, G., Ludivico, C., Bao, M., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207281 · Cited by 117 · see citing works
Fleischmann, R., Halland, A., Brzosko, M., Burgos-Vargas, R., Mela, C., Vernon, E., & Kremer, J. (2013) · Journal of Rheumatology · doi:10.3899/jrheum.120447 · Cited by 112 · see citing works
Huizinga, T. W. J., Conaghan, P. G., Martín-Mola, E., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205752 · Cited by 109 · see citing works
Bykerk, V., Östör, A., Álvaro-Gracia, J., Pavelka, K., Ivorra, J., Graninger, W., Bensen, W., Nurmohamed, M., Krause, A., Bernasconi, C., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201087 · Cited by 107 · see citing works
Low immunogenicity of tocilizumab in patients with rheumatoid arthritis
Burmester, G., Choy, E., Kivitz, A., Ogata, A., Bao, M., Nomura, A., Lacey, S., Pei, J., Reiss, W., Pethoe-Schramm, A., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210297 · Cited by 99 · see citing works
Moots, R., Sebba, A., Rigby, W., Ostor, A., Porter-Brown, B., Donaldson, F., Dimonaco, S., Rubbert-Roth, A., van Vollenhoven, R., & Genovese, M. (2016) · Rheumatology · doi:10.1093/rheumatology/kew370 · Cited by 91 · see citing works
Genovese, M. C., Kremer, J. M., van Vollenhoven, R., Alten, R., Scali, J. J., Kelman, A., Dimonaco, S., & Brockwell, L. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40176 · Cited by 86 · see citing works
Burmester, G., Rigby, W., van Vollenhoven, R., Kay, J., Rubbert-Roth, A., Blanco, R., Kadva, A., & Dimonaco, S. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210561 · Cited by 77 · see citing works
Gabay, C., Riek, M., Hetland, M. L., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207760 · Cited by 71 · see citing works
Weinblatt, M., Kremer, J., Cush, J., Rigby, W., Teng, L.-C. L., Devenport, J., Singh, N., Lepley, D., & Genovese, M. (2013) · Arthritis care & research · doi:10.1002/acr.21847 · Cited by 60 · see citing works
Morel, J., Constantin, A., Baron, G., Dernis, E., Flipo, R., Rist, S., Combe, B., Gottenberg, J., Schaeverbeke, T., Soubrier, M., et al. (2017) · Rheumatology · doi:10.1093/rheumatology/kex238 · Cited by 57 · see citing works
Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab
Rubbert-Roth, A., Sebba, A., Brockwell, L., Kelman, A., Porter-Brown, B., Pulley, J., Napalkov, P., & van Vollenhoven, R. (2016) · RMD Open · doi:10.1136/rmdopen-2015-000213 · Cited by 55 · see citing works
Curtis, J., Perez-Gutthann, S., Suissa, S., Napalkov, P., Singh, N., Thompson, L., & Porter-Brown, B. (2015) · Seminars in Arthritis & Rheumatism · doi:10.1016/j.semarthrit.2014.07.006 · Cited by 53 · see citing works
Choy, E., Bernasconi, C., Aassi, M., et al. (2017) · Arthritis Care & Research · doi:10.1002/acr.23303 · Cited by 50 · see citing works
Ogata, A., Amano, K., Dobashi, H., Inoo, M., Ishii, T., Kasama, T., Kawai, S., Kawakami, A., Koike, T., Miyahara, H., et al. (2015) · Journal of Rheumatology · doi:10.3899/jrheum.140665 · Cited by 46 · see citing works
Kremer, J., Rigby, W., Singer, N. G., Birchwood, C., Gill, D., Reiss, W., Pei, J., & Michalska, M. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40493 · Cited by 46 · see citing works
on behalf of the British Society for Rheumatology Biologics Register, Kihara, M., Davies, R., et al. (2016) · Clinical Rheumatology · doi:10.1007/s10067-016-3485-5 · Cited by 45 · see citing works
Backhaus, M., Kaufmann, J., Richter, C., Wassenberg, S., Roske, A., Hellmann, P., & Gaubitz, M. (2015) · Clinical Rheumatology · doi:10.1007/s10067-015-2879-0 · Cited by 44 · see citing works
Iking-Konert, C., von Hinüber, U., Richter, C., Schwenke, H., Gürtler, I., Kästner, P., Klapperich, B., Peters, M., & Burmester, G. (2016) · Rheumatology · doi:10.1093/rheumatology/kev372 · Cited by 42 · see citing works
Immunogenicity of tocilizumab in patients with rheumatoid arthritis.
Sigaux, J., Hamze, M., Daien, C., Morel, J., Krzysiek, R., Pallardy, M., Maillère, B., Mariette, X., & Miceli-Richard, C. (2017) · Joint, bone, spine : revue du rhumatisme · doi:10.1016/j.jbspin.2016.04.013 · Cited by 40 · see citing works
Monemi, S., Berber, E., Sarsour, K., Wang, J., Lampl, K., Bharucha, K., & Pethoe-Schramm, A. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0037-z · Cited by 38 · see citing works
Jones, G., Wallace, T., McIntosh, M. J., et al. (2016) · The Journal of Rheumatology · doi:10.3899/jrheum.160287 · Cited by 38 · see citing works
Safety profile of biological therapies for treating rheumatoid arthritis
Cañete, J. D. D., Hernández, M. V., & Sanmartí, R. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1346078 · Cited by 35 · see citing works
Intravenous Tocilizumab: A Review of Its Use in Adults with Rheumatoid Arthritis
Dhillon, S. (2013) · BioDrugs · doi:10.1007/s40259-013-0076-8 · Cited by 30 · see citing works
Kremer, J. M., Blanco, R., Halland, A.-M., et al. (2016) · PubMed · Cited by 25 · see citing works
Kivitz, A., Wallace, T., Olech, E., Borofsky, M., Devenport, J., Pei, J., & Michalska, M. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0043-1 · Cited by 25 · see citing works
Paul, S. K., Montvida, O., Best, J. H., et al. (2017) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2017.08.001 · Cited by 25 · see citing works
Giles, J. (2016) · Arthritis & Rheumatism · Cited by 20 · see citing works
Terreaux, W., Masson, C., Eschard, J., et al. (2017) · Joint Bone Spine · doi:10.1016/j.jbspin.2017.01.002 · Cited by 19 · see citing works
Haraoui, B., Casado, G. C., Czirják, L., et al. (2018) · PubMed · Cited by 18 · see citing works
Flipo, R., Maillefert, J., Chazerain, P., Idier, I., Coudert, M., & Tebib, J. (2017) · RMD Open · doi:10.1136/rmdopen-2016-000340 · Cited by 13 · see citing works
OP0105 Long-term safety of tocilizumab from large clinical trial and postmarketing populations
Mohan, S., Michalska, M., Yourish, J., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-eular.3573 · Cited by 6 · see citing works
Lauper, K., Nordström, D., Pavelká, K., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-eular.6503 · Cited by 4 · see citing works
FRI0202 Safe and Effective Tocilizumab Therapy in Elderly Patients with Rheumatoid Arthritis
Specker, C., Kaufmann, J., Kellner, H., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-eular.3424 · Cited by 3 · see citing works
Kremer, J. M., Rigby, W., Singer, N. G., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-eular.2797 · Cited by 3 · see citing works
Choy, E., Caporali, R. F., Xavier, R. M., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-eular.1615 · Cited by 3 · see citing works
Kremer, J. M., Rigby, W., Singer, N. G., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-eular.1838 · Cited by 3 · see citing works
Strand, V., Lampl, K. L., Birchwood, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-eular.3312 · Cited by 2 · see citing works
Harrold, L., Reed, G. W., Best, J. D., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-eular.3295 · Cited by 1 · see citing works
PETERFY, C. G., Kremer, J. M., Rigby, W., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-eular.1741 · Cited by 1 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [66]Kim SC, Solomon DH, Rogers JR, et al. Cardiovascular safety of tocilizumab versus abatacept in patients with rheumatoid arthritis: a multi-database study [abstract no. 527]. Arthr Rheumatol. 2017;69(Suppl 10). PMC5573926 28245350
Cited by
Sorted by citations
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
Guaraldi, G., Meschiari, M., Cozzi-Lepri, A., Milic, J., Tonelli, R., Menozzi, M., Franceschini, E., Cuomo, G., Orlando, G., Borghi, V., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30173-9 · Cited by 939 · see citing works
Veiga, V. C., Prats, J. A. G. G., Farias, D. L. C., Rosa, R. G., Dourado, L. K., Zampieri, F. G., Machado, F. R., Lopes, R. D., Berwanger, O., Azevedo, L. C. P., et al. (2021) · BMJ · doi:10.1136/bmj.n84 · Cited by 388 · see citing works
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222 · see citing works
- Authors
- Scott, L. J.
- Affiliations
- Springer Nature (New Zealand) (NZ)
- Corresponding author
- Scott, Lesley J.
- Venue
- Drugs
- Published
- 2017-11
- Volume
- 77
- Issue
- 17
- Pages
- 1865-1879
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- PMC
- PMC5736769
- OpenAlex
- W2765166506
- Cited by
- 419
- References
- 71
- Citations by year
- 2026: 28 · 2025: 46 · 2024: 44 · 2023: 60 · 2022: 52 · 2021: 74 · 2020: 79 · 2019: 29 · 2018: 7
- FWCI
- 27.38
- Type
- journal article
- Language
- en
- Update notices
- correction (2017-12-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Drugs (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Keywords
- tocilizumab, rheumatoid arthritis, IL-6 receptor inhibitor, subcutaneous tocilizumab, intravenous tocilizumab, methotrexate combination therapy, conventional synthetic DMARDs, biologic therapy, treatment efficacy, drug safety, immunogenicity, radiographic outcomes, health-related quality of life
- MeSH terms
- Arthritis, Rheumatoid, Humans, Methotrexate, Antirheumatic Agents, Receptors, Interleukin-6, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
